Innovation Files: Where Tech Meets Public Policy

R&D Costs, Rx Prices, and the Formula for Success in Life Sciences Innovation, With Stephen Ezell

Nov 15, 2021

27:55

Creator website

Highlights

AI Chapters

Episode notes

Prescription Drug Prices - Are They Too High?

04:30

Is the Federal Government Taking Over Drug Development?

04:24

The Cost of Drug Discovery and Development

05:43

Introduction

3min

Is the Federal Government Taking Over Drug Development?

4min

The Chinese Biotechnology Ecosystem

3min

Prescription Drug Prices - Are They Too High?

5min

The Cost of Drug Discovery and Development

6min

Is the Rate of Return on a Covin Vaccine Really Important?

2min

Is There a Conflict Between Intellectual Property Rights and Access to Medicines?

5min

The United States is the leader in life sciences innovation, but that has not always been the case. As global competition intensifies, it needs to continue spurring investment in R&D to stay on top. Rob and Jackie sat down with Stephen Ezell, vice president of global innovation policy at ITIF, to discuss the history of U.S. life sciences innovation and break down R&D costs versus the market prices of innovative biopharmaceuticals.

Mentioned

Anusuya Chatterjee and Ross C. DeVol, “Estimating Long-Term Economic Returns of NIH Funding on Output in the Biosciences” (Milken Institute, 2012), 4.

Related

Rob Atkinson and Stephen Ezell, “Five Fatal Flaws in Rep. Katie Porter’s Indictment of the U.S. Drug Industry” (ITIF, May 2021).
Joe Kennedy, “The Link Between Drug Prices and Research on the Next Generation of Cures” (ITIF, September 2019).
Event, “How Intellectual Property Has Played a Pivotal Role in the Global COVID-19 Response,” (ITIF, April 2021).

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.